SPORE in Prostate Cancer

  • Young, Charles (PI)
  • Fatemi, Mostafa (PI)
  • Morris, John C. (PI)
  • Thibodeau, Stephen Norman (PI)
  • Vile, Richard (PI)
  • Vasmatzis, George (PI)
  • Jenkins, Robert B. (PI)
  • Bergstralh, Eric J. (PI)
  • Cheville, John (PI)
  • Klee, George (PI)
  • Tindall, Donald J. (PI)
  • Davis, Brian (PI)
  • Sargent, Daniel (PI)
  • Layton, Donald (PI)
  • Vuk-Pavlovic, Stanimir (PI)
  • Celis, Esteban (PI)

Project: Research project

Description

DESCRIPTION (provided by applicant):
This Specialized Program of Research Excellence (SPORE) in prostate cancer at
the Mayo Clinic Comprehensive Cancer Center will support a multidisciplinary
team of basic, clinical, and population science investigators to perform
translational research directed at significantly reducing mortality from
prostate carcinoma. Donald J. Tindall, Ph.D. will serve as the Principal
Investigator. Michael M. Liebet, M.D. will serve as Co-Principal
Investigator. The translational research objectives of the SPORE will be
directed by six research projects: Project 1: Genetic Susceptibility in
Prostate Cancer (Stephen N. Thibodeau, Ph.D., Michael L. Blute, M.D., Daniel
J. Schaid, Ph.D., James R. Cerhan: M.D., Ph.D., Steven J. Jacobsen, M.D.,
Ph.D.) Project 2: Human Kallikreins as Novel Markers of Prostate Cancer
(Charles Y.F. Young, George G. Klee, M.D., Ph.D. Donald J. Tindall, Ph.D.,
Michael Liebet, M.D.). Project 3: Biologic and Clinical Studies of the
Over-represented 8q24 Region Associated with Prostate Cancer Progression
(Robert B. Jenkins, M.D., Ph.D., Michael M. Liebet, M.D.). Project 4: An
Immune-Based Therapeutic Approach for Prostate Cancer, (Esteban Celis, M.D.,
Ph.D., Patrick A. Burch, M.D.,). Project 5: Use of Fusogeoic Membrane
Glycoproteins for Gene Therapy of Prostate Cancer (Richard G. Vile, Ph.D.,
Evanthia Galahis, M.D., Brian J. Davis, M.D., Torrance Wilson, M.D.). Project
6: Gene Therapy of Prostate Cancer using Radioactive Iodine (John C. Morris
III, M.D., Brian J. Davis, M.D., Esteban Celis, M.D., Richard G. Vile, Ph.D.).
Five core resources will support these research projects: Core 1:
Administrative Core (Donald J. Tindall, Ph.D.). Core 2: Prostate Cancer
Tissue Resource Core (John C. Cheville, M.D., Patrick Roche, Ph.D.). Core 3:
Gene Discovery and Bioinformatics Core (George Vasmatzis, Ph.D., Stephen J.
Itturria, Ph.D.). Core 4: Clinical Follow-up Core (Brian J. Davis, M.D., Mike
Blute M.D., Patrick A. Burch, M.D., Thomas M. Pisansky, M.D.). Core 5:
Biostatistics Core (Daniel J. Sargent, Ph.D., Susan Geyer, Ph.D., Erik J.
Bergstrahl, M.S.). A Developmental Research Program has been established to
explore opportunities for innovative research and a Career Development Program
has been organized to facilitate young investigators to establish independence
in prostate cancer translational research. The SPORE structure provides the
ideal mechanism to focus and integrate the discovery efforts of investigators
and to optimally utilize the clinical resources of the Mayo Clinic practice to
make meaningful advances in the management of prostate cancer.
StatusFinished
Effective start/end date8/31/018/31/13

Funding

  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health

Fingerprint

Prostatic Neoplasms
Cytotoxic T-Lymphocytes
Helper-Inducer T-Lymphocytes
Neoplasms
Therapeutics
Peptides
T-Lymphocyte Epitopes
T-Lymphocytes
Prostate
Cancer Vaccines
Subunit Vaccines
Neoplasm Antigens
Therapeutic Uses
Epitopes
Immune System
Research
Antigens
Cell- and Tissue-Based Therapy
Dendritic Cells
Translational Medical Research

ASJC

  • Medicine(all)